IP Library › Granted Patent US 12,201,612
Granted Patent B2
US 12,201,612 · App. 16/634,986 · Granted Jan 21, 2025

Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use

Inventors: Ricardo Carl Elciario Dolmetsch (Concord, MA); Fabrizio Gasparini (Weiherhofstrasse, CH); Baltazar Gomez-Mancilla (Basel, CH); Donald Johns (Woburn, MA)
Assignee: NOVARTIS AG
A61K31/403A61K45/06A61P25/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,612
App. No.
16/634,986
Granted
Jan 21, 2025
Kind
B2
Abstract

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol use disorder.

Claims (13)

1. A method for reduction of alcohol use by an alcohol use disorder patient, in need thereof, comprising administering to said alcohol use disorder patient 200 mg/b.i.d. of mavoglurant, or a pharmaceutically acceptable salt thereof.

2. A method according to claim 1 , wherein alcohol use disorder is associated with high risk drinking for acute problems.

3. A method according to claim 1 , wherein alcohol use disorder is comorbid with a psychiatric disorder.

4. A method according to claim 1 , wherein administration of mavoglurant, or a pharmaceutically acceptable salt thereof is combined with standardized psychological treatment.

5. A method according to claim 1 , wherein administration of mavoglurant, or a pharmaceutically acceptable salt thereof is combined with psychosocial or behavioral therapy or combination thereof.

6. A method according to claim 5 , wherein the psychosocial or the behavioral therapy is computer-assisted.

7. A method according to claim 1 , wherein administration of mavoglurant, or a pharmaceutically acceptable salt thereof, is concomitant with methadone or buprenorphine treatment.

8. A method according to claim 1 , wherein mavoglurant, or a pharmaceutically acceptable salt thereof, is administered in combination with a further active agent.

9. A method according to claim 1 , wherein the patient has a genetic variation associated with a substance use disorder.

10. A method according to claim 1 , wherein mavoglurant, or a pharmaceutically acceptable salt thereof, is administered in an immediate-release form or a modified release form.

11. A method according to claim 1 , wherein alcohol use disorder is associated with daily alcohol consumption 60 g/day of ethanol for men and 40 g/day for women.

12. A method according to claim 3 , wherein the psychiatric disorder is chosen from antisocial personality disorder, borderline personality disorder, depression, anxiety, schizophrenia, attention deficit hyperactivity disorder, bipolar disorder, obsessive compulsive disorder, and binge eating disorder.

13. A method according to claim 9 , wherein the patient has a genetic variation associated with alcohol use disorder.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2020
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
To: NOVARTIS AG
Reel/Frame 052725/0462 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2020
From: DOLMETSCH, RICARDO
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Reel/Frame 052725/0757 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2020
From: JOHNS, DONALD
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Reel/Frame 052725/0846 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2020
From: GOMEZ-MANCILLA, BALTAZAR; GASPARINI, FABRIZIO
To: NOVARTIS PHARMA AG
Reel/Frame 052725/0936 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2020
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 052726/0058 →
Continuity (2)
Provisional Application 62539008 · Jul 31, 2017
Related Publication 20200237721A1 · Jul 30, 2020
References Cited (28)
US 8574626B2 · Vergez et al. · 2013 [cited by applicant]
US 8703809B2 · Gomez-Mancilla et al. · 2014 [cited by applicant]
US 9770423B2 · Erickson et al. · 2017 [cited by applicant]
US 10336687B2 · Cacciaglia et al. · 2019 [cited by applicant]
US 20160000736A1 · Cohen et al. · 2016 [cited by applicant]
US 20160128979A1 · Thoma et al. · 2016 [cited by applicant]
US 20180230086A1 · Cacciaglia et al. · 2018 [cited by applicant]
US 20210069150A1 · Galli et al. · 2021 [cited by applicant]
EP 1267869B1 · 2004 [cited by applicant]
JP 2015524805A · 2015 [cited by applicant]
JP 2016520663A · 2016 [cited by applicant]
WO 2006089494A1 · 2006 [cited by applicant]
WO 2012117073A2 · 2012 [cited by applicant]
WO 2015197079A1 · 2015 [cited by applicant]
WO 2017021438A1 · 2017 [cited by applicant]
Bacstrom et al., mGluR5 Antagonist MPEP Reduces Ethanol-Seeking and Relapse Behavior. Neuropsychopharmacology, 2004, 29 , 921-928. [cited by examiner]
Rehm J. R. The Risks Associated with Alcohol Use and Alcoholism. Alcohol Research & Health, 2011, 34, 135-143. [cited by examiner]
McKetin et al., Recreational drug use and binge drinking: Stimulant but not cannabis intoxication is associated with excessive alcohol consumption. Drug and Alcohol Review, 2014, 33, 436-445. [cited by examiner]
Haile et al., Genetics of Dopamine and its Contribution to Cocaine Addiction. Behavior Genetics, 2007, 37, 119-145. [cited by examiner]
Kiluk et al., Quality versus quantity: acquisition of coping skills following computerized cognitive-behavioral therapy for substance use disorder. Addiction, 2010, 105, 2120-2127. [cited by examiner]
Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism, Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. R… [cited by examiner]
Olive et al., “The mGluR5 Antagonist 6-methyl-2-(phenylethynyl)pyridine Decreases Ethanol Consumption via a Protein Kinase C Epsilon-Dependent Mechanism,” Mol Pharmacol. 67(2):349-55 (2005). [cited by applicant]
International Search Report mailed Nov. 6, 2018 for PCT International Application No. PCT/IB2018/055665 (3 pages). [cited by applicant]
Keck et al., “Fenobam sulfate inhibits cocaine-taking and cocaine-seeking behavior in rats: implications for addiction treatment in humans,” Psychopharmacology, Apr. 25, 2013, pp. 253-265, vol. 229, Springer. [cited by applicant]
Office Action in corresponding JP application 2020-503275 dated Jan. 24, 2023 (pp. 1-3) and English translation thereof. [cited by applicant]
Parkitna et al.: “Novility Seeking Behaviors and the Escalation of Alcohol Drinking After Abstinence in Mice Are Controlled by Metabolopic Glutamate Receptor 5 on Neurons Expressing Dopamine D1 Receptors”, Biol Psychiat… [cited by applicant]
Office Action in corresponding KR application 10-2020-7002167 dated Oct. 10, 2023 (pp. 1-8) and English translation thereof. [cited by applicant]
Celine Ellen Francois de Esch, “Therapeutic Targets and Translational Endpoints in Fragile X Syndrome” 2014 (pp. 1-142) ISBN: 978-94-6182-448-6. [cited by applicant]
Cited By (1)
US 12,415,795